BioNTech SE - ADR vs Vanguard Real Estate Index Fund ETF — how do they compare? BioNTech SE - ADR trades at $90.48 (market cap $22.86B), while Vanguard Real Estate Index Fund ETF trades at $98.67. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | VNQ | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | — |
52-Week High | $119.34 | $98.66 |
52-Week Low | $83.89 | $87.00 |
Enterprise Value | $6.53B | — |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
VNQ (Vanguard Real Estate ETF) trades at $97.87, up 0.57% today, with a bullish technical signal from moving averages. The ETF shows strong momentum in the real estate sector, benefiting from AI-driven data center REIT performance. Recent news highlights REITs outpacing the broader market despite interest rate pressures, with VNQ being the default choice for real estate exposure.
The outlook for VNQ remains positive as real estate fundamentals strengthen, with dividends rising and M&A activity intensifying. Key risks include persistent high interest rates and inflation volatility. Wall Street sentiment is cautiously optimistic, focusing on durable income streams and sector recovery potential amid macroeconomic uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →